Nov 07, 2023 / 04:10PM GMT
Debjit D. Chattopadhyay - Guggenheim Securities, LLC, Research Division - Senior Analyst of Biotechnology
Good morning and thank you for joining us at Guggenheim's 5th Annual I&I and Neurology Conference, I am Debjit and it's our privilege to host Onaiza Cadoret, EVP and Chief Global Product Strategy and Operational Officer at Ionis along with Brett Monia, Chief Executive Officer. Thank you. Thank you both for your time today. Brett, why don't you sort of lead us off with an overview of the company heading into a very data-rich period for Ionis over the next 2 years?
Brett P. Monia - Ionis Pharmaceuticals, Inc. - Founder, CEO & Director
Sure. Happy to, Debjit and good morning, everybody. Thank you for the opportunity to be here and speak on behalf of Ionis. So we -- Ionis is right now on the cusp of really driving substantial value for all Ionis stakeholders today. Looking back to last year, we had a very positive Phase III data for eplontersen in TTR amyloidosis with polyneuropathy. This year, we had a drug approval, QALSODY, for SOD1-ALS, which
Ionis Pharmaceuticals Inc at Guggenheim Securities Inflammation & Immunology Conference Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers